IN2012DN00720A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00720A
IN2012DN00720A IN720DEN2012A IN2012DN00720A IN 2012DN00720 A IN2012DN00720 A IN 2012DN00720A IN 720DEN2012 A IN720DEN2012 A IN 720DEN2012A IN 2012DN00720 A IN2012DN00720 A IN 2012DN00720A
Authority
IN
India
Prior art keywords
nucleic acid
acid prodrugs
chiral phosphorous
phosphorous moieties
prodrugs
Prior art date
Application number
Other languages
English (en)
Inventor
Gregory L Verdine
Meena Meena
Naoki Iwamoto
Original Assignee
Ontorii Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43429503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ontorii Inc filed Critical Ontorii Inc
Publication of IN2012DN00720A publication Critical patent/IN2012DN00720A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IN720DEN2012 2009-07-06 2010-07-06 IN2012DN00720A (instruction)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22336909P 2009-07-06 2009-07-06
US24272209P 2009-09-15 2009-09-15
PCT/US2010/041068 WO2011005761A1 (en) 2009-07-06 2010-07-06 Novel nucleic acid prodrugs and methods use thereof

Publications (1)

Publication Number Publication Date
IN2012DN00720A true IN2012DN00720A (instruction) 2015-06-19

Family

ID=43429503

Family Applications (1)

Application Number Title Priority Date Filing Date
IN720DEN2012 IN2012DN00720A (instruction) 2009-07-06 2010-07-06

Country Status (15)

Country Link
US (2) US9744183B2 (instruction)
EP (1) EP2451461A4 (instruction)
JP (2) JP5998326B2 (instruction)
KR (1) KR101885383B1 (instruction)
CN (1) CN102596204B (instruction)
AU (1) AU2010270714B2 (instruction)
BR (1) BR112012000828A8 (instruction)
CA (1) CA2767253A1 (instruction)
CL (1) CL2012000021A1 (instruction)
IL (1) IL217370A (instruction)
IN (1) IN2012DN00720A (instruction)
MX (1) MX342945B (instruction)
RU (1) RU2612521C2 (instruction)
SG (2) SG10201403841QA (instruction)
WO (1) WO2011005761A1 (instruction)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101806314B1 (ko) * 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
IN2012DN00720A (instruction) 2009-07-06 2015-06-19 Ontorii Inc
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
RU2014105311A (ru) * 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
CN104661664B (zh) * 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
IN2015DN01765A (instruction) * 2012-08-20 2015-05-29 Univ California
SI2961388T1 (sl) * 2013-03-01 2019-10-30 Astex Pharmaceuticals Inc Kombinacije zdravil
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
CA2936712A1 (en) 2014-01-16 2015-07-23 Meena Chiral design
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
DK3234131T3 (da) 2014-12-16 2020-06-29 Roche Innovation Ct Copenhagen As Fremgangsmåde til screening af kiral toksicitet
RU2711506C2 (ru) 2014-12-17 2020-01-17 ПРОКЬЮЭР ТЕРАПЬЮТИКС II Би.Ви. Редактирование целевой рнк
US20180207197A1 (en) * 2015-06-26 2018-07-26 Kyowa Hakko Kirin Co., Ltd. Oligonucleotide derivative
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN108137492B (zh) 2015-10-09 2021-12-21 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
CN114685589A (zh) 2016-03-13 2022-07-01 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
JP7017517B2 (ja) * 2016-03-18 2022-02-08 ロシュ イノベーション センター コペンハーゲン エーエス アシル保護l-lna-グアノシンモノマー
EA201892366A1 (ru) 2016-04-18 2019-03-29 Сарепта Терапьютикс, Инк. Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы
JP7042255B2 (ja) 2016-04-29 2022-03-25 サレプタ セラピューティクス, インコーポレイテッド ヒトlmnaを標的にするオリゴヌクレオチド類縁体
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
CA3024944A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
TW201811807A (zh) 2016-06-30 2018-04-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
MX2019000660A (es) * 2016-07-15 2019-10-02 Sperovie Biosciences Inc Compuestos, composiciones y métodos para el tratamiento de enfermedades.
KR20190058477A (ko) 2016-08-17 2019-05-29 솔스티스 바이올로직스, 리미티드 폴리뉴클레오티드 구축물
EP3503730B1 (en) 2016-08-23 2023-09-27 Dicerna Pharmaceuticals, Inc. Compositions comprising reversibly modified oligonucleotides and uses thereof
IL264923B2 (en) 2016-09-01 2025-07-01 Proqr Therapeutics Ii Bv Single-stranded RNA-editing oligonucleotides with chemical modifications
EP3544987A4 (en) 2016-11-23 2020-11-18 Wave Life Sciences Ltd. COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
AU2017382723B2 (en) 2016-12-19 2025-01-30 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CN110636866B (zh) 2016-12-19 2024-10-18 萨勒普塔医疗公司 用于肌肉萎缩症的外显子跳跃寡聚体缀合物
EP3554554B1 (en) 2016-12-19 2022-09-07 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
WO2018181428A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
KR20190135494A (ko) * 2017-03-29 2019-12-06 로슈 이노베이션 센터 코펜하겐 에이/에스 입체한정된 포스포로티오에이트 올리고뉴클레오티드의 제조를 위한 직교 보호기
WO2018223056A1 (en) * 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN120249271A (zh) 2017-06-02 2025-07-04 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3664816A4 (en) * 2017-08-08 2021-05-19 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES
KR20200052369A (ko) 2017-09-18 2020-05-14 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 제조 기술
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
US20200254002A1 (en) 2017-09-28 2020-08-13 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687547A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
CN107892710B (zh) * 2017-10-10 2021-04-13 河北大学 一种易于回收循环使用的负载型铂配合物氧化剂及其制备方法和应用
JP2020537518A (ja) 2017-10-12 2020-12-24 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法
JP7394753B2 (ja) 2017-10-18 2023-12-08 サレプタ セラピューティクス, インコーポレイテッド アンチセンスオリゴマー化合物
CN112218664A (zh) 2018-05-11 2021-01-12 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
US20200190516A1 (en) 2018-12-13 2020-06-18 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystropy
EP3901161B1 (en) * 2019-01-10 2025-01-22 Shenzhen YING Biopharmaceutical Co., Ltd. Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof
WO2020212301A1 (en) 2019-04-16 2020-10-22 Roche Innovation Center Copenhagen A/S Novel process for preparing nucleotide p(v) monomers
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
WO2021234459A2 (en) 2020-05-22 2021-11-25 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
TW202241454A (zh) * 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
WO2023055774A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4590311A2 (en) 2022-09-21 2025-07-30 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024093947A1 (zh) * 2022-10-31 2024-05-10 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024168093A2 (en) * 2023-02-08 2024-08-15 Toreador Therapeutics, Inc. Super-resolution microscopy (srm) multiplexing with cleavable moieties
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024227040A1 (en) 2023-04-27 2024-10-31 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of chronic kidney disease
AR132964A1 (es) 2023-06-16 2025-08-13 Proqr Therapeutics Ii Bv Oligonucleótidos antisentido para el tratamiento de enfermedades neurodegenerativas
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025051946A1 (en) 2023-09-07 2025-03-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025085810A2 (en) 2023-10-18 2025-04-24 Sarepta Therapeutics, Inc. Antisense oligomers for treatment of centronuclear myopathies
WO2025104239A1 (en) 2023-11-16 2025-05-22 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025132708A1 (en) 2023-12-20 2025-06-26 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease

Family Cites Families (685)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3135766A (en) 1961-10-03 1964-06-02 Mead Johnson & Co 3-substituted-3-pyrrolidinols
US3484473A (en) 1967-05-12 1969-12-16 Buckman Labor Inc Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de) 1968-07-10 1970-01-15 Pennwalt Corp Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3745162A (en) 1970-08-31 1973-07-10 Robins Co Inc A H 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en) 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US4022791A (en) 1975-06-03 1977-05-10 Pfizer Inc. 2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
BR7807288A (pt) 1977-11-08 1979-06-12 Genentech Inc Processo para sintese de polinucleotidos
DD133885B1 (de) 1978-01-04 1981-02-25 Hans Lehmann Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4542142A (en) 1982-11-22 1985-09-17 Roussel Uclaf Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (de) 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr) 1985-02-01 1988-01-08 Lafon Labor Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
JPH0658512B2 (ja) 1985-04-12 1994-08-03 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4840956A (en) 1986-02-18 1989-06-20 Warner-Lambert Company Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
US4735949A (en) 1986-02-18 1988-04-05 Warner-Lambert Company Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
IL83663A0 (en) 1986-10-27 1988-01-31 Robins Co Inc A H Preparation of 3-pyrrolidinols
JP2828642B2 (ja) 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
EP0302349B1 (en) 1987-07-30 1993-09-29 Bar Ilan University Biologically active carboxylic acid esters
US4923901A (en) 1987-09-04 1990-05-08 Millipore Corporation Membranes with bound oligonucleotides and peptides
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4945158A (en) 1988-08-12 1990-07-31 American Cyanamid Company Antidiabetic phosphonates
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja) 1989-08-17 1998-09-03 有機合成薬品工業株式会社 ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
JPH05503517A (ja) 1989-12-18 1993-06-10 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンド及びその用途
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5635488A (en) 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
WO1991010671A1 (en) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5914396A (en) 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5852188A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals, Inc. Oligonucleotides having chiral phosphorus linkages
US5292875A (en) 1990-04-20 1994-03-08 Lynx Therapeutics, Inc. Method of synthesizing sulfurized oligonucleotide analogs
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69131773T2 (de) 1990-05-23 2000-03-02 Isis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns "5'-cap-struktur"
US5834607A (en) 1990-07-27 1998-11-10 Isis Pharmaceuticals, Inc. Amines and methods of making and using the same
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US6121433A (en) 1990-07-27 2000-09-19 Isis Pharmaceuticals, Inc. Oligomeric compounds having nitrogen-containing linkages
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
WO1992002258A1 (en) 1990-07-27 1992-02-20 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US6087482A (en) 1990-07-27 2000-07-11 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
WO1994022886A1 (en) 1993-03-30 1994-10-13 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5783682A (en) 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5792844A (en) 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en) 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US20020183502A1 (en) 1991-05-21 2002-12-05 Mesmaeker Alain De Backbone-modified oligonucleotide analogs and methods for using same
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
WO1992022655A1 (en) 1991-06-10 1992-12-23 Lucky Limited Hepatitis c diagnostics and vaccines
US5359052A (en) 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en) 1991-08-05 1997-07-08 Polish Academy Of Sciences Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5654284A (en) 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5576302A (en) 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5661134A (en) 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5607923A (en) 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
ATE221127T1 (de) * 1991-10-15 2002-08-15 Isis Pharmaceuticals Inc Über chirale phosphoratome gebundene oligonukleotide
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
CA2126691C (en) 1991-12-24 2003-05-06 Phillip Dan Cook Gapped 2' modified oligonucleotides
GB9213601D0 (en) 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
DE69400208T2 (de) 1993-01-25 1996-11-28 Hybridon Inc Olionukleotidalkylphosphonate und -phosphonothioate
HU9501994D0 (en) 1993-03-31 1995-09-28 Sterling Winthrop Inc Novel 5'-substituted nucleosides and oligomers produced therefrom
JPH08508489A (ja) 1993-03-31 1996-09-10 スターリング ウィンスロップ インコーポレイティド 二官能価ヌクレオシド、それらのオリゴマーならびにそれらの製造方法及び使用方法
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
DE69412704T2 (de) 1993-06-10 1999-02-04 Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo Spritzgiessform
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5643989A (en) * 1993-10-29 1997-07-01 Azdel, Inc. Fiber reinforced functionalized polyolefin composites
WO1998003542A1 (en) 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de) 1994-01-19 1995-07-20 Boehringer Mannheim Gmbh Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
DE69527835T2 (de) 1994-02-22 2003-04-10 Novozymes A/S, Bagsvaerd Methode zur herstellung einer variante eines lipolytischen enzymes
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
EP0759073A1 (en) 1994-05-11 1997-02-26 Novo Nordisk A/S AN ENZYME WITH ENDO-1,3(4)-$g(b)-GLUCANASE ACTIVITY
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
DK0685475T3 (da) 1994-05-31 1999-08-30 Bayer Ag Amino-benzofuryl- og thienylderivater
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69521517T2 (de) 1994-09-07 2002-04-18 Hybridon, Inc. Prodrug-oligonukleotide
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
CA2208528A1 (en) 1994-12-22 1996-06-27 Hybridon, Inc. Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en) 1995-01-25 1995-03-15 King S College London Nucleoside phosphorothioate derivatives,synthesis and use thereof
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DE69638104D1 (de) 1995-04-27 2010-02-11 Takara Bio Inc Für Lacto-N-biosidase kodierendes Gen
ES2220929T3 (es) 1995-05-11 2004-12-16 Applied Research Systems Ars Holding N.V. Inhibidor de la actividad il-6.
AU5855296A (en) 1995-05-19 1996-11-29 Glycomed Incorporated Collection of activated glycoside compounds and their biolog ical use
AU5871196A (en) 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
DK0836612T3 (da) 1995-05-23 2000-10-30 Hybridon Inc Nye synthoner til stereoselektiv oligonucleotidsyntese
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5932450A (en) 1995-06-07 1999-08-03 Gen-Probe Incorporated Enzymatic synthesis of oligonucleotides using digestible templates
DE69635849T2 (de) 1995-06-29 2006-10-19 Takara Bio Inc., Otsu Für Endoglycoceramidase kodierendes Gen
EP0759470B1 (en) 1995-06-29 2006-10-25 Takara Bio Inc. Gene encoding endoglycoceramidase activator
US6017700A (en) 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en) 1996-05-24 1999-08-10 Genta Incorporated Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en) 1995-09-05 1997-03-13 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
EP1007655A4 (en) 1996-02-15 2000-06-14 Nat Inst Health RNASE L AND ANTISENSE OLIGONUCLEOTIDE ACTIVATORS FOR TREATING RSV INFECTIONS
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
WO1997043409A2 (en) 1996-05-10 1997-11-20 Novo Nordisk A/S Method of providing novel dna sequences
US5856465A (en) 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19622783A1 (de) 1996-06-07 1997-12-11 Hoechst Ag Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
EP0912767B1 (en) 1996-07-16 2006-09-13 Gen-Probe Incorporated Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm
WO1998007734A1 (en) * 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
GB9621522D0 (en) 1996-10-16 1996-12-04 Biocompatibles Ltd Synthesis of phosphorus compounds
US6639062B2 (en) 1997-02-14 2003-10-28 Isis Pharmaceuticals, Inc. Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6369237B1 (en) 1997-03-07 2002-04-09 President And Fellows Of Harvard College DNA glycosylase inhibitors, and uses related thereto
US6015887A (en) 1997-04-11 2000-01-18 Isis Pharmaceuticals, Inc. Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en) 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl) 1997-04-25 2002-11-29 Pan Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
AU745309B2 (en) 1997-05-28 2002-03-21 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
CA2295110A1 (en) 1997-06-27 1999-01-07 The Procter & Gamble Company Pro-fragrance cyclic acetals
AU8512598A (en) 1997-07-25 1999-02-16 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
GB9717158D0 (en) 1997-08-13 1997-10-22 King S College London Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US6528640B1 (en) 1997-11-05 2003-03-04 Ribozyme Pharmaceuticals, Incorporated Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6080543A (en) 1997-12-08 2000-06-27 E. & J. Gallo Winery Detection of fungal pathogens
US6582936B1 (en) 1997-12-12 2003-06-24 The Regents Of The University Of California Methods for making nucleic acids
US6248519B1 (en) 1998-03-11 2001-06-19 E & J Gallo Winery Detection of fermentation-related microorganisms
US7045610B2 (en) 1998-04-03 2006-05-16 Epoch Biosciences, Inc. Modified oligonucleotides for mismatch discrimination
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
NZ508650A (en) 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
CA2333854A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation Stereoisomers of cpg oligonucleotides and related methods
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
WO2000023444A1 (en) 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
WO2000031110A1 (en) 1998-11-25 2000-06-02 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
US6451524B1 (en) 1998-11-25 2002-09-17 Isis Pharmaceuticals, Inc. Identification of disease predictive nucleic acids
WO2000037658A2 (en) 1998-12-21 2000-06-29 Genencor International, Inc. Chemically modified enzymes with multiple charged variants
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US6265172B1 (en) 1999-02-08 2001-07-24 University Of Kentucky Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en) 1999-03-29 1999-05-26 Goldsborough Andrew Cleavage of nucleic acids from solid supports
JP3072345B1 (ja) 1999-03-31 2000-07-31 農林水産省家畜衛生試験場長 豚丹毒菌の組換えサブユニットワクチン
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en) 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en) 1999-06-25 2001-08-07 Display Systems Biotech A/S Method for improved reverse transcription at high temperatures
US6066500A (en) 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7264932B2 (en) 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
HRP20020249A2 (en) 1999-09-25 2005-06-30 University Of Iowa Research Foundation Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en) 1999-09-30 2002-06-27 Scott Henry Use of oligonucleotides for inhibition of complement activation
US6528262B1 (en) 1999-10-06 2003-03-04 Quark Biotech, Inc. Method for enrichment of natural antisense messenger RNA
GB9924285D0 (en) 1999-10-14 1999-12-15 Avecia Ltd Process
US20010055761A1 (en) 1999-10-29 2001-12-27 Agilent Technologies Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr) 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
WO2001040515A1 (en) 1999-11-12 2001-06-07 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en) 1999-12-27 2001-11-27 Technion Research And Development Foundation Ltd. Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
US7055094B2 (en) 1999-12-30 2006-05-30 Rutgers, The State University Of New Jersey Virtual tags and the process of virtual tagging utilizing user feedback in transformation rules
US7501091B2 (en) 1999-12-30 2009-03-10 Smiths Detection Inc. Sensors with improved properties
US6649750B1 (en) 2000-01-05 2003-11-18 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotide compounds
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6936432B2 (en) 2000-03-01 2005-08-30 Message Pharmaceuticals Bacterial RNase P proteins and their use in identifying antibacterial compounds
GB0004889D0 (en) 2000-03-01 2000-04-19 Avecia Ltd Synthesis of oligonucleotides
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
MXPA02010261A (es) 2000-04-20 2003-04-25 Hoffmann La Roche Derivados de pirrolidina y piperidina y su uso para el tratamiento de transtornos neurodegenerativos.
DE10019756A1 (de) 2000-04-20 2001-10-25 Bayer Ag Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
US20020013287A1 (en) * 2000-05-09 2002-01-31 Reliable Biopharmaceuticals, Inc. St Louis Missouri Polymeric compounds useful as prodrugs
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
JP4331476B2 (ja) 2000-08-03 2009-09-16 エフ.ホフマン−ラ ロシュ アーゲー プリン−2,6−ジアミンのピラゾロ[3,4−d]ピリミジンアナローグを含有する核酸結合性化合物およびそれらの使用
US6725412B1 (en) 2000-08-15 2004-04-20 Dolby Laboratories Licensing Corporation Low latency data encoder
US6809195B1 (en) 2000-08-16 2004-10-26 Isis Pharmaceuticals, Inc. Process for the preparation of oligonucleotides
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
CA2419894A1 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Process for high throughput screening of cpg-based immuno-agonist/antagonist
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
GB0024752D0 (en) 2000-10-10 2000-11-22 Univ Belfast Oxidative halogenation of aromatic compounds
WO2002032450A2 (en) 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccines
US6372492B1 (en) 2000-10-30 2002-04-16 Isis Pharmaceuticals, Inc. Antisense modulation of talin expression
US6682889B1 (en) 2000-11-08 2004-01-27 Becton, Dickinson And Company Amplification and detection of organisms of the Chlamydiaceae family
NL1016978C2 (nl) 2000-12-22 2002-06-25 Robert Jan Colenbrander Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
EA007491B1 (ru) 2001-01-22 2006-10-27 Мерк Энд Ко., Инк. Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
ATE501251T1 (de) 2001-01-25 2011-03-15 Evolva Ltd Zellbibliothek
EP1354035B1 (en) 2001-01-26 2016-08-24 Commonwealth Scientific and Industrial Research Organisation Methods and means for producing efficient silencing construct using recombinational cloning
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2002097134A2 (en) 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
GB0113523D0 (en) 2001-06-04 2001-07-25 Torotrak Dev Ltd An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en) 2001-06-14 2003-04-10 Isis Pharmaceuticals, Inc. Methods for preparing oligonucleotides having chiral phosphorothioate linkages
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
NZ530632A (en) 2001-06-29 2007-04-27 Chiron Corp HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides
WO2003004602A2 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US6440739B1 (en) 2001-07-17 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
CA2458393A1 (en) 2001-08-24 2003-03-06 Massachusetts Institute Of Technology Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en) 2001-09-21 2006-05-23 Academia Sinica Mutant-type lipases and applications thereof
US6933288B2 (en) 2002-02-04 2005-08-23 Isis Pharmaceuticals, Inc. Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja) 2002-02-12 2009-10-21 株式会社キラルジェン 立体規則性の高いジヌクレオシドホスホロチオエートの製造法
US20040149587A1 (en) 2002-02-15 2004-08-05 George Hradil Electroplating solution containing organic acid complexing agent
US20030159938A1 (en) 2002-02-15 2003-08-28 George Hradil Electroplating solution containing organic acid complexing agent
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
US7288376B2 (en) 2002-03-22 2007-10-30 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of huntingtin interacting protein 2 expression
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
WO2003097662A1 (en) 2002-05-15 2003-11-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040014108A1 (en) 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
US7507808B2 (en) 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20040005338A1 (en) 2002-06-20 2004-01-08 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004003228A1 (en) 2002-07-01 2004-01-08 Unisearch Limited Genotyping method
EP2333062A1 (en) 2002-07-10 2011-06-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
US20040023905A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of LAR expression
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US8729036B2 (en) 2002-08-07 2014-05-20 University Of Massachusetts Compositions for RNA interference and methods of use thereof
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
KR101360955B1 (ko) 2002-09-13 2014-02-10 레플리코르 인코포레이티드 비서열 상보적 항바이러스 올리고뉴클레오티드
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
US20040147020A1 (en) 2002-11-01 2004-07-29 The Regents Of The University Of Colorado, A Body Corporate Dopamine neurons from human embryonic stem cells
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044141A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
WO2004044133A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
AU2003291721A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Phosphorous-linked oligomeric compounds and their use in gene modulation
US7381527B2 (en) 2002-11-06 2008-06-03 Council Of Scientific And Industrial Research Method of detection of SP-A2 gene variants
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
EP2336318B1 (en) 2002-11-13 2013-04-24 Genzyme Corporation Antisense modulation of apolipoprotein b expression
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
EP2239329A1 (en) 2003-03-07 2010-10-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en) 2003-03-24 2003-04-30 Avecia Ltd Process and compounds
WO2004084939A2 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US20090247488A1 (en) 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
BRPI0409680A (pt) 2003-04-25 2006-04-18 Gilead Sciences Inc análogos de fosfonato anti-cáncer
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7045306B2 (en) 2003-04-28 2006-05-16 The General Hospital Corporation Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
JP4179562B2 (ja) 2003-05-14 2008-11-12 独立行政法人科学技術振興機構 ハンチンチン遺伝子の発現抑制
BRPI0410886A (pt) * 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
JP2011088935A (ja) 2003-08-08 2011-05-06 Chiralgen Ltd リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
MXPA06001976A (es) 2003-08-21 2006-05-31 Univ Griffith Nuevas sulfenamidas.
CA2535800A1 (en) 2003-08-21 2005-03-03 Griffith University Novel sulfenamide oxides
CN1863813B (zh) 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
WO2005023828A1 (ja) 2003-09-02 2005-03-17 Takeshi Wada リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
JP4616175B2 (ja) 2003-09-02 2011-01-19 株式会社キラルジェン 5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
CA2579638C (en) 2003-09-12 2016-04-19 University Of Massachusetts Rna interference targeting non-disease causing single nucleotide polymorphisms within a gene encoding a gain-of-function mutant huntingtin protein
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
NZ546475A (en) 2003-10-30 2008-08-29 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en) 2003-10-31 2005-10-27 Verdine Gregory L Nucleic acid binding oligonucleotides
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
WO2005063983A1 (en) 2003-12-29 2005-07-14 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005070859A1 (ja) 2004-01-27 2005-08-04 Takeshi Wada フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
WO2005076744A2 (en) 2004-02-18 2005-08-25 Frutarom Ltd. Method for the preparation of peptide-oligonucleotide conjugates
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2005085272A1 (ja) 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
JP4865544B2 (ja) 2004-03-25 2012-02-01 株式会社キラルジェン 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
WO2005097817A2 (en) 2004-04-05 2005-10-20 Alnylam Pharmaceuticals, Inc. Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
WO2005116268A2 (en) 2004-05-27 2005-12-08 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Differential expression of molecules associated with acute stroke
US7759318B1 (en) 2004-05-28 2010-07-20 Isis Pharmaceuticals, Inc. Identification of novel pathways, genes and promoter motifs regulating adipogenesis
EP1765416A4 (en) 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
PL2409713T3 (pl) 2004-08-10 2016-02-29 Kastle Therapeutics Llc Oligonukleotydy do zastosowania w modulowaniu poziomów lipoproteiny i cholesterolu u ludzi
CN101048423B (zh) 2004-08-26 2011-06-08 日本新药株式会社 亚磷酰胺化合物及低聚核糖核酸的制备方法
EP1791557A4 (en) 2004-09-07 2009-09-23 Archemix Corp MEDICAL CHEMISTRY USING APTAMERS
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20090203132A1 (en) 2004-09-09 2009-08-13 Swayze Eric E Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
WO2006034348A2 (en) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
WO2006044531A2 (en) 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (en) 2004-11-16 2006-05-17 Immunotech S.A. Oligonucleotides that induce the secretion of GM-CSF
AU2005313883B2 (en) 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en) 2004-12-17 2006-06-22 Thiosense, Inc. Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20070099851A1 (en) 2004-12-30 2007-05-03 Linn Gregory S Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
WO2006080596A1 (en) 2005-01-28 2006-08-03 Hyung-Joo Kwon Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
EP1851314A2 (en) 2005-02-24 2007-11-07 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
WO2006137953A1 (en) 2005-04-01 2006-12-28 The Regents Of The Univerisity Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
EP2062586B1 (en) 2005-05-05 2017-03-15 Autotelic LLC Use of low doses of oligonucleotides antisense to tgf-beta1 genes in the treatment of tumors
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
WO2006121960A2 (en) 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
EP2644700A1 (en) 2005-06-23 2013-10-02 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of SMN2 splicing
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1896586A2 (en) 2005-06-28 2008-03-12 Medtronic, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1948600B1 (en) 2005-07-05 2014-04-16 The President & Fellows Of Harvard College Liver targeted conjugates
JP4984634B2 (ja) 2005-07-21 2012-07-25 ソニー株式会社 物理情報取得方法および物理情報取得装置
WO2007016379A2 (en) 2005-07-28 2007-02-08 Id-Fish Technology, Inc. Method for improving cell permeability to foreign particles
DE602006019455D1 (de) 2005-08-29 2011-02-17 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
US8501703B2 (en) 2005-08-30 2013-08-06 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en) 2005-09-30 2007-04-05 Midgley Timothy M Method and apparatus for collecting user game play data and crediting users in a gaming environment
CN104278037B (zh) 2005-10-12 2020-09-15 艾德拉药物股份有限公司 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CN101365801B (zh) 2005-10-28 2013-03-27 阿尔尼拉姆医药品有限公司 抑制亨廷顿基因表达的组合物和方法
CA2627134A1 (en) 2005-10-28 2007-05-03 Tosoh Corporation Method of preparing carotenoid synthesizing microorganism and method of producing carotenoids
EP1963502A4 (en) * 2005-11-11 2010-04-07 Pfizer COMBINATIONS AND METHOD FOR USE OF AN IMMUNOMODULATIVE OLIGODESOXYNUCLEOTIDE
WO2007064291A1 (en) 2005-11-30 2007-06-07 Jyoti Chattopadhyaya Method and compounds for rna synthesis
EP1957507B1 (en) 2005-12-02 2018-10-24 Ionis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
DK1979356T3 (da) 2005-12-21 2013-11-18 Pfizer Prod Inc Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
PL2161038T3 (pl) 2006-01-26 2014-06-30 Ionis Pharmaceuticals Inc Kompozycje i ich zastosowanie ukierunkowane na huntingtynę
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
EP1991678B2 (en) 2006-02-15 2020-07-15 Rechtsanwalt Thomas Beck Compositions and methods for oligonucleotide formulations
US7759470B2 (en) 2006-02-20 2010-07-20 Roche Diagnostics Operations, Inc. Labeling reagent
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AU2007234451A1 (en) 2006-03-31 2007-10-11 Atom Acquisition, Llc Reagents useful for synthesizing rhodamine-labeled oligonucleotides
WO2007118222A2 (en) 2006-04-06 2007-10-18 Ibis Biosciences, INC Compositions for the use in identification of fungi
CN101472904B (zh) 2006-04-20 2012-06-06 弗·哈夫曼-拉罗切有限公司 趋化因子受体的二氮杂环庚烷衍生物调节剂
EP2020449B1 (en) 2006-04-24 2012-09-26 Sigma Alimentos, S.A. De C.V. Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
US20100008937A1 (en) 2006-04-25 2010-01-14 Immune Disease Institute, Inc. Targeted delivery to leukocytes using non-protein carriers
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8158598B2 (en) 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
WO2007143317A2 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc Compounds and methods for modulating expression of crp
US20090012120A1 (en) 2006-05-10 2009-01-08 Board Of Trustees Of Michigan State University Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CN101460620B (zh) 2006-05-31 2012-02-15 东丽株式会社 免疫刺激寡核苷酸及其药物用途
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
CA2662704A1 (en) 2006-07-07 2008-01-10 University Of Massachusetts Rna silencing compositions and methods for the treatment of huntington's disease
JP6125741B2 (ja) 2006-07-12 2017-05-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
US7666888B2 (en) 2006-07-20 2010-02-23 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
AU2007281082A1 (en) 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
AT504194B1 (de) 2006-09-07 2008-07-15 Oesterr Rotes Kreuz Bakteriennachweis
US8138330B2 (en) 2006-09-11 2012-03-20 Sigma-Aldrich Co. Llc Process for the synthesis of oligonucleotides
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 T 유사체를 함유하는 CpG 올리고뉴클레오티드 유사체
EP3916095A1 (en) 2006-10-18 2021-12-01 Ionis Pharmaceuticals, Inc. Antisense compounds
CN101589047A (zh) 2006-10-23 2009-11-25 Irm责任有限公司 组织蛋白酶类抑制剂
CN101558157A (zh) 2006-10-26 2009-10-14 科勒制药有限责任公司 寡核糖核苷酸及其应用
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
JP2010510224A (ja) 2006-11-17 2010-04-02 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのアミノピロリジン類
MX2009005527A (es) 2006-11-27 2009-06-08 Isis Pharmaceuticals Inc Metodos para el tratamiento de hipercolesterolemia.
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CN101610671A (zh) 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
RU2559536C2 (ru) 2007-03-24 2015-08-10 Джензим Корпорейшн Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
EP2158316B1 (en) 2007-05-11 2015-04-15 Adynxx, Inc. Gene expression and pain
US8222407B2 (en) 2007-05-24 2012-07-17 Kyorin Pharmaceutical Co., Ltd. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en) 2007-05-29 2007-07-04 Texas Instr Denmark PWM loop with minimum allasing error property
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2164865A2 (en) 2007-06-13 2010-03-24 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
DE602007005629D1 (de) 2007-06-18 2010-05-12 Commissariat Energie Atomique Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
CN102921003B (zh) 2007-07-09 2014-11-26 艾德拉药物股份有限公司 稳定化免疫调控性rna(simra)化合物
TWI413530B (zh) 2007-07-20 2013-11-01 Kao Corp 有機聚矽氧
EP2185723A4 (en) 2007-07-31 2011-01-12 Univ Saskatchewan EFFECT OF A GENETIC VARIATION IN THE GENESIS OF PROMELANIN CONCENTRATING HORMONE ON THE MEAT PROPERTIES IN BOVINE ANIMALS
WO2009017803A2 (en) 2007-08-02 2009-02-05 The Texas A & M University System Antisense microrna and uses therefor
US8853375B2 (en) 2007-08-15 2014-10-07 Idera Pharmaceuticals, Inc. Toll like receptor modulators
KR101660989B1 (ko) 2007-10-01 2016-09-28 아이오니스 파마수티컬즈, 인코포레이티드 섬유아세포 성장 인자 수용체 4 발현의 안티센스 조절
KR100886139B1 (ko) 2007-11-13 2009-02-27 주식회사 삼천리제약 올리고뉴클레오타이드의 제조방법
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
TWI340765B (en) 2007-12-26 2011-04-21 Ind Tech Res Inst Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
WO2009098197A1 (en) 2008-02-04 2009-08-13 Biofocus Dpi B.V. Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (ja) 2008-02-12 2009-08-27 Tokyo Institute Of Technology オリゴヌクレオチド誘導体
WO2009117589A1 (en) 2008-03-21 2009-09-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
US20110269814A1 (en) 2008-03-26 2011-11-03 Alnylam Pharamaceuticals, Inc. 2'-f modified rna interference agents
KR101806314B1 (ko) 2008-04-03 2017-12-07 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
EP2262820B1 (de) 2008-04-04 2013-06-19 Universität Hamburg Verfahren zur stereoselektiven synthese von phosphorverbindungen
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
AU2009244013B2 (en) 2008-05-09 2015-06-25 The University Of British Columbia Methods and compositions for the treatment of Huntington's disease
US8679750B2 (en) 2008-05-09 2014-03-25 The University Of British Columbia Methods and compositions for the treatment of Huntington'S disease
EP2300102B1 (en) 2008-05-15 2014-01-08 Dynavax Technologies Corporation Immunostimulatory sequences containing CpG for use in the treatment of allergic rhinitis
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
WO2009143391A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
EP2294181A4 (en) 2008-05-22 2013-04-24 Isis Pharmaceuticals Inc MODULATION OF SMRT EXPRESSION
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス, インコーポレイテッド Cdkモジュレーター
US8410070B2 (en) 2008-09-12 2013-04-02 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
WO2010030858A1 (en) 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
EP2346883B1 (en) 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
CA2739788A1 (en) 2008-10-07 2010-04-15 President And Fellows Of Harvard College Telomerase inhibitors that bind to the cr4-cr5 domain of the rna component of human telomerase and methods of use thereof
CA2962219C (en) 2008-10-22 2020-08-25 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
JP5763539B2 (ja) 2008-10-24 2015-08-12 アイシス ファーマシューティカルズ, インコーポレーテッド 5’及び2’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物
EP2447274B1 (en) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
CA2747999A1 (en) 2008-12-23 2010-07-01 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
WO2010080953A1 (en) 2009-01-08 2010-07-15 Isis Pharmaceuticals, Inc. Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
US20120264806A1 (en) 2009-02-06 2012-10-18 Bennett C Frank Oligomeric compounds and excipients
JP2012517226A (ja) 2009-02-10 2012-08-02 イデラ ファーマシューティカルズ インコーポレイテッド Tlr7の合成rnaベースのアゴニスト
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US9107933B2 (en) 2009-03-16 2015-08-18 Isis Pharmaceuticals, Inc. Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
EP2415777B1 (en) 2009-03-31 2015-07-29 Takeda Pharmaceutical Company Limited Process for producing nucleoside
US8987222B2 (en) 2009-04-08 2015-03-24 University Of Massachusetts Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
WO2010120262A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
WO2010129853A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
EP2438079A4 (en) 2009-06-01 2013-05-22 Univ California NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF
EP3124491B1 (en) 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법
JP5670097B2 (ja) 2009-06-19 2015-02-18 花王株式会社 二層分離型毛髪化粧料
JPWO2010150789A1 (ja) 2009-06-23 2012-12-10 武田薬品工業株式会社 核酸の合成法
WO2011005764A1 (en) 2009-07-06 2011-01-13 Ada Technologies, Inc. Electrochemical device and method for long-term measurement of hypohalites
IN2012DN00720A (instruction) 2009-07-06 2015-06-19 Ontorii Inc
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US20110009477A1 (en) 2009-07-08 2011-01-13 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
EP2458005A1 (en) 2009-07-23 2012-05-30 Galaxy Pharma Inc. Fgf21 cis-element binding substance
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en) 2009-08-10 2015-01-06 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides and uses thereof
DK2475675T3 (en) 2009-09-11 2017-02-06 Ionis Pharmaceuticals Inc MODULATION OF HUNTINGTIN EXPRESSION
US8470987B2 (en) 2009-09-16 2013-06-25 Chiralgen, Ltd. Protective group for synthesis of RNA and derivative
EP2480667A4 (en) 2009-09-25 2013-07-03 Isis Pharmaceuticals Inc MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
EA201290147A1 (ru) 2009-10-15 2012-11-30 Пфайзер Инк. Пирроло[2,3-d]пиримидиновые соединения
TWI475051B (zh) 2009-11-18 2015-03-01 Kao Corp Organic polysiloxane
JP5809408B2 (ja) 2009-11-25 2015-11-10 花王株式会社 毛髪化粧料
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
KR101433114B1 (ko) 2009-12-28 2014-08-22 아키라 랩스 프라이빗 리미티드 진단용 겔 조성물, 진단용 겔 조성물의 제조 방법
CA2786071C (en) 2010-01-08 2021-01-12 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US8750507B2 (en) 2010-01-25 2014-06-10 Cisco Technology, Inc. Dynamic group creation for managed key servers
US9006198B2 (en) 2010-02-08 2015-04-14 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
DK2534248T3 (en) 2010-02-08 2018-11-19 Ionis Pharmaceuticals Inc SELECTIVE REDUCTION OF ALLELVARIANS
MX2012009316A (es) 2010-02-10 2012-09-12 Glaxosmithkline Llc Maleato de 6-amino-2-{ [ (1s) -1-metil-butil] -oxi} -9-[ 5-(1-piperidinil) -7, 9-dihidro-8h-purin-8-ona.
CN102918052A (zh) 2010-03-05 2013-02-06 国立大学法人东京大学 硫代磷酸核糖核苷的制造方法
WO2011127175A1 (en) 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cd130 (gp130) expression
JP2013527148A (ja) 2010-04-07 2013-06-27 アイシス ファーマシューティカルズ, インコーポレーテッド Cetp発現の調節
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EP2625186B1 (en) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
EP2563921B1 (en) 2010-04-30 2016-11-23 Cellectis Method for modulating double-strand break-induced homologous recombination
GB201008902D0 (en) 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
EP3406730B1 (en) 2010-08-31 2022-02-23 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
JP5996431B2 (ja) 2010-09-30 2016-09-21 Lsipファンド運営合同会社 優性変異遺伝子発現抑制剤
KR101381048B1 (ko) 2010-10-20 2014-04-14 씨제이제일제당 (주) O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2012073857A1 (ja) 2010-11-30 2012-06-07 株式会社キラルジェン 2'-o-修飾rna
WO2012092367A1 (en) 2010-12-28 2012-07-05 University Of Rochester Nucleic acid binding compounds, methods of making, and use thereof
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CA2827380C (en) 2011-02-12 2020-08-25 University Of Iowa Research Foundation Therapeutic nucleic acids
US9353371B2 (en) 2011-05-02 2016-05-31 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
AU2012283994A1 (en) 2011-07-19 2014-03-06 University Of Idaho Embodiments of a probe and method for targeting nucleic acids
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
EP3922722B1 (en) 2011-08-11 2023-06-28 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2751269B1 (en) 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
DK2751284T3 (en) 2011-08-31 2017-03-27 Univ Manchester PROCEDURE FOR DIAGNOSTICING A NEURODEGENERATIVE DISEASE
WO2013036833A1 (en) 2011-09-09 2013-03-14 Mayo Foundation For Medical Education And Research Detecting frontotemporal dementia and amyotrophic lateral sclerosis
EP2785729B1 (en) 2011-11-30 2020-11-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
KR200460641Y1 (ko) 2011-12-07 2012-06-04 이형호 휴대가 용이한 와인 잔
US10557136B2 (en) 2011-12-12 2020-02-11 Oncolmmunin Inc. In vivo delivery of oligonucleotides
CA3106312A1 (en) 2011-12-16 2013-06-20 National University Corporation Tokyo Medical And Dental University Chimeric double-stranded nucleic acid
CN102675386B (zh) 2011-12-24 2014-07-02 河南科技大学 一种龙胆苦苷分离提纯方法
US8957042B2 (en) 2012-03-07 2015-02-17 The Texas A&M University System Cancer treatment targeting non-coding RNA overexpression
EP3210993B1 (en) 2012-03-13 2018-12-12 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
KR20130114435A (ko) 2012-04-09 2013-10-17 삼성전자주식회사 다수의 전극을 갖는 생분자 검출 장치
EP2841578B1 (en) 2012-04-23 2017-06-07 BioMarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
US20130315868A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
IN2014DN10144A (instruction) 2012-05-30 2015-08-21 Hokkaido System Science Co Ltd
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
WO2014025805A1 (en) 2012-08-06 2014-02-13 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugated rna agents and process for their preparation
WO2014028739A1 (en) 2012-08-15 2014-02-20 Isis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
CA2887884A1 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
HK1212597A1 (zh) 2012-10-15 2016-06-17 Isis Pharmaceuticals, Inc. 用於調節c90rf72表達的組合物
EP2906696B2 (en) 2012-10-15 2022-12-14 Ionis Pharmaceuticals, Inc. Methods for modulating c9orf72 expression
JP2015535261A (ja) 2012-10-29 2015-12-10 コクリスタル ファーマ,インコーポレイテッド ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
WO2014069520A1 (ja) 2012-10-31 2014-05-08 武田薬品工業株式会社 新規修飾核酸
AU2013346767B2 (en) 2012-11-15 2019-04-11 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CA2889993A1 (en) 2012-11-26 2014-05-30 Roche Innovation Center Copenhagen A/S Compositions and methods for modulation of fgfr3 expression
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
SG11201505387PA (en) 2013-01-30 2015-08-28 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates
WO2014121287A2 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9896688B2 (en) 2013-02-22 2018-02-20 Sirna Therapeutics, Inc. Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage
CA2901983A1 (en) 2013-03-01 2014-09-04 National University Corporation Tokyo Medical And Dental University Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
MX2015013628A (es) 2013-03-28 2016-02-18 Syngenta Ltd Metodos para controlar las plagas resistentes a neonicotinoides.
WO2014154488A1 (en) 2013-03-28 2014-10-02 Syngenta Participations Ag Methods of controlling neonicotinoid resistant pests
RU2670614C9 (ru) 2013-05-01 2018-11-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии hbv и ttr
BR112015029327A2 (pt) 2013-05-24 2017-09-19 Roche Innovation Ct Copenhagen As Moduladores de oligonucleotídeo de linfoma 11a/cll de célula b (bcl11a) e usos dos mesmos
EP3015467B1 (en) 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Morpholino oligonucleotide manufacturing method
WO2014192310A1 (en) 2013-05-30 2014-12-04 National University Corporation Tokyo Medical And Dental University Double-stranded agents for delivering therapeutic oligonucleotides
CA2915443A1 (en) 2013-06-16 2014-12-24 National University Corporation Tokyo Medical And Dental University Double-stranded antisense nucleic acid with exon-skipping effect
EP3011028B1 (en) 2013-06-21 2019-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
RS59986B1 (sr) 2013-06-27 2020-03-31 Roche Innovation Ct Copenhagen As Antisens oligomeri i konjugati koji ciljno deluju na pcsk9
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
WO2015017675A2 (en) 2013-07-31 2015-02-05 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
CN105579442A (zh) 2013-09-06 2016-05-11 先正达参股股份有限公司 杀虫化合物
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
EP4166667A3 (en) 2013-10-11 2023-08-02 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
CA2926341A1 (en) 2013-10-14 2015-04-23 Ionis Pharmaceuticals, Inc. Methods for modulating expression of c9orf72 antisense transcript
EP3058068B1 (en) 2013-10-14 2019-04-24 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
NZ719477A (en) 2013-11-11 2022-05-27 Sangamo Therapeutics Inc Methods and compositions for treating huntington’s disease
RU2016122168A (ru) 2013-11-14 2017-12-19 Рош Инновейшен Сентер Копенгаген А/С Антисмысловые конъюгаты, направленные на аполипопротеин b
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CA2936712A1 (en) 2014-01-16 2015-07-23 Meena Chiral design
US10280418B2 (en) 2014-03-18 2019-05-07 Univeristy Of Massachusetts RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
DK3137476T3 (da) 2014-04-28 2019-11-18 Ionis Pharmaceuticals Inc Linker-modificerede oligomerforbindelser
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
RU2691102C2 (ru) 2014-05-08 2019-06-11 Сангамо Байосайенсиз, Инк. Способы и композиции для лечения болезни хантингтона
RU2711147C2 (ru) 2014-05-20 2020-01-15 Юниверсити Оф Айова Рисерч Фаундейшн Терапевтические соединения для лечения болезни хантингтона
US20160017327A1 (en) 2014-07-11 2016-01-21 The Johns Hopkins University Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
EP4159741A1 (en) 2014-07-16 2023-04-05 ModernaTX, Inc. Method for producing a chimeric polynucleotide encoding a polypeptide having a triazole-containing internucleotide linkage
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
KR101882634B1 (ko) 2014-08-07 2018-07-26 다케다 야쿠힝 고교 가부시키가이샤 양이온성 지질
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016037191A1 (en) 2014-09-05 2016-03-10 Health Research, Inc. Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
HK1244843A1 (zh) 2014-11-17 2018-08-17 Alnylam Pharmaceuticals, Inc. 载脂蛋白c3(apoc3)irna组合物及其使用方法
JP2017536119A (ja) 2014-11-19 2017-12-07 ロシュ イノベーション センター コペンハーゲン エーエス キラルホスホロチオエート連結を含むlnaギャップマーオリゴヌクレオチド
DK3234131T3 (da) 2014-12-16 2020-06-29 Roche Innovation Ct Copenhagen As Fremgangsmåde til screening af kiral toksicitet
LT3237618T (lt) 2014-12-24 2019-07-10 Uniqure Ip B.V. Rnri sukeltas hantingtino geno slopinimas
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
HK1248276A1 (zh) 2015-02-04 2018-10-12 F. Hoffmann-La Roche Ag Tau 反义低聚物及其用途
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
PE20171382A1 (es) 2015-02-10 2017-09-15 Genzyme Corp ARNi VARIANTE
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016138017A1 (en) 2015-02-23 2016-09-01 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing antisense activity
US20180036335A1 (en) 2015-03-03 2018-02-08 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016154096A1 (en) 2015-03-20 2016-09-29 Ionis Pharmaceuticals, Inc. Modulation of smggds expression
ES2808750T3 (es) 2015-04-03 2021-03-01 Univ Massachusetts Compuestos oligonucleotídicos dirigidos a ARNm de huntingtina
US10851371B2 (en) 2015-04-10 2020-12-01 Ionis Pharmaceuticals, Inc. Modulation of SMN expression
SG10202001856WA (en) 2015-04-16 2020-04-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
JP2018519811A (ja) 2015-06-29 2018-07-26 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 修飾crispr rna及び修飾単一crispr rnaならびにその使用
MY192997A (en) 2015-07-10 2022-09-20 Ionis Pharmaceuticals Inc Modulators of diacyglycerol acyltransferase 2 (dgat2)
WO2017011286A1 (en) 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
DK3324980T3 (da) 2015-07-17 2022-02-14 Alnylam Pharmaceuticals Inc Multimålrettede enkeltenhedskonjugater
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US20180216114A1 (en) 2015-07-27 2018-08-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
HK1256683A1 (zh) 2015-07-31 2019-10-04 阿尔尼拉姆医药品有限公司 甲状腺素运载蛋白(ttr)irna组合物及其治疗或预防ttr相关疾病的使用方法
US20190055550A1 (en) 2015-08-24 2019-02-21 Roche Innovation Center Copenhagen A/S LNA-G Process
NZ779375A (en) 2015-08-25 2025-05-30 Alnylam Pharmaceuticals Inc Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
PE20181131A1 (es) 2015-09-02 2018-07-17 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
EP3356447A4 (en) 2015-10-01 2019-06-12 Memorial Sloan-Kettering Cancer Center INHIBITORS OF MENACHINONE BIOSYNTHESIS
US10874686B2 (en) 2015-10-01 2020-12-29 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
CN108136041B (zh) 2015-10-02 2022-12-30 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合方法
CN108137492B (zh) 2015-10-09 2021-12-21 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP3183347A4 (en) 2015-10-17 2018-04-18 Lifesplice Pharma LLC Splice modulating oligonucleotides and methods of use thereof
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017068087A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S Oligonucleotide detection method
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
EP3374498A1 (en) 2015-11-12 2018-09-19 H. Hoffnabb-La Roche Ag Standardized neuronal cell assays from primate species
CN114685589A (zh) 2016-03-13 2022-07-01 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
LT3430141T (lt) 2016-03-14 2021-03-25 F. Hoffmann-La Roche Ag Oligonukleotidai, skirti pd-l1 raiškai sumažinti
JP7017517B2 (ja) 2016-03-18 2022-02-08 ロシュ イノベーション センター コペンハーゲン エーエス アシル保護l-lna-グアノシンモノマー
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
WO2017180835A1 (en) 2016-04-13 2017-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
CN109153697A (zh) 2016-04-14 2019-01-04 豪夫迈·罗氏有限公司 三苯甲基-单-GalNAc化合物及其用途
MA45290A (fr) 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
EP3455232B1 (en) 2016-05-12 2020-05-06 Roche Innovation Center Copenhagen A/S Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
CN109072234B (zh) 2016-05-13 2022-11-29 豪夫迈·罗氏有限公司 基于蛋白质的样品采集基质和装置
EP3458464A1 (en) 2016-05-18 2019-03-27 ETH Zurich Stereoselective synthesis of phosphorothioate oligoribonucleotides
CN109562122A (zh) 2016-06-03 2019-04-02 波涛生命科学有限公司 寡核苷酸、组合物及其方法
EP3473270B1 (en) 2016-06-20 2022-11-30 Genahead Bio, Inc. Antibody-drug conjugate
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
EP3544987A4 (en) 2016-11-23 2020-11-18 Wave Life Sciences Ltd. COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES

Also Published As

Publication number Publication date
CN102596204B (zh) 2016-11-23
BR112012000828A8 (pt) 2017-10-10
CL2012000021A1 (es) 2012-07-20
EP2451461A1 (en) 2012-05-16
IL217370A (en) 2017-09-28
MX342945B (es) 2016-10-18
US9744183B2 (en) 2017-08-29
AU2010270714A1 (en) 2012-02-16
KR101885383B1 (ko) 2018-08-03
RU2012102480A (ru) 2013-08-20
JP2012532199A (ja) 2012-12-13
CA2767253A1 (en) 2011-01-13
JP5998326B2 (ja) 2016-09-28
AU2010270714B2 (en) 2015-08-13
SG177564A1 (en) 2012-02-28
US20120316224A1 (en) 2012-12-13
IL217370A0 (en) 2012-02-29
WO2011005761A8 (en) 2012-02-02
BR112012000828A2 (pt) 2016-02-23
MX2012000380A (es) 2012-05-23
WO2011005761A1 (en) 2011-01-13
KR20120046238A (ko) 2012-05-09
RU2612521C2 (ru) 2017-03-09
CN102596204A (zh) 2012-07-18
US10307434B2 (en) 2019-06-04
EP2451461A4 (en) 2013-05-29
JP2015205910A (ja) 2015-11-19
US20160347784A1 (en) 2016-12-01
SG10201403841QA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
IN2012DN00720A (instruction)
MX2011013421A (es) Arnds formulado con lipido de direccionamiento del gen pcsk9.
GB201209132D0 (en) Compositions and methods for targeted nucleic acid sequence selection and amplification
PL2563739T3 (pl) Sposób wytwarzania cegieł przy zastosowaniu bakterii wytwarzającej enzym
EP2248906A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
SG10201503327QA (en) Production of nucleic acid
GB0910302D0 (en) Nucleic acid amplification
MX349630B (es) Alfa-amilasas.
EP2322472A4 (en) METHODS OF PRODUCING PHOSPHORUS PENTAFLUORIDE AND HEXAFLUOROPHOSPHATES
PL2488542T3 (pl) Fosfolipazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i zastosowania
EP2499166A4 (en) IMPROVED ENZYMATIC HYDROLYSIS METHODS
EP2113570A4 (en) PROCESS FOR PRODUCTION OF L-AMINO ACID
IL216109A0 (en) Production of ammonium phosphates
ZA201102120B (en) Improved method of rna display
EP2460883A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
ZA201105632B (en) Method of amplification of gc-rich dna templates
EG26913A (en) Method for producing phosphoric acid
EP2405006A4 (en) MICROORGANISM FOR THE MANUFACTURE OF L-AMINO ACIDS AND METHOD FOR THE PRODUCTION OF L-AMINO ACIDS THEREWITH
EP2328907A4 (en) HYDROLASES, NUCLEIC ACIDS COORDINATING THEREFOR, AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2195453A4 (en) METHOD FOR AMPLIFYING NUCLEIC ACID
IL217247A0 (en) Dermaseptin b2 as an inhibitor of tumor growth
EP2497832A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
EP2455470A4 (en) PROCESS FOR NUCLEIC ACID AMPLIFICATION
HRP20210761T8 (hr) Postupak izrade cigle pomoću bakterije koja proizvodi enzime
GB0903266D0 (en) Enzymatic process